Discovery - University of Dundee - Online Publications

Library & Learning Centre

The anti-neurodegenerative agent clioquinol regulates the transcription factor FOXO1a

The anti-neurodegenerative agent clioquinol regulates the transcription factor FOXO1a

Research output: Contribution to journalArticle

View graph of relations

Authors

  • Amy R. Cameron
  • Katherine Wallace
  • Lisa Logie
  • Alan R. Prescott
  • Terry G. Unterman
  • Jean Harthill
  • Graham Rena (Lead / Corresponding author)

Research units

Info

Original languageEnglish
Pages57-64
Number of pages8
JournalBiochemical Journal
Journal publication date1 Apr 2012
Journal number1
Volume443
DOIs
StatePublished

Abstract

Many diseases of aging including AD (Alzheimer's disease) and T2D (Type 2 diabetes) are strongly associated with common risk factors, suggesting that there may be shared aging mechanisms underlying these diseases, with the scope to identify common cellular targets for therapy. In the present study we have examined the insulin-like signalling properties of an experimental AD 8-hydroxyquinoline drug known as CQ (clioquinol). The IIS [insulin/IGF-1 (insulin-like growth factor-1) signalling] kinase Akt/PKB (protein kinase B) inhibits the transcription factor FOXO1a (forkhead box O1a) by phosphorylating it on residues that trigger its exit from the nucleus. In HEK (human embryonic kidney)-293 cells, we found that CQ treatment induces similar responses. A key transcriptional response to US is the inhibition of hepatic gluconeogenic gene expression, and, in rat liver cells, CQ represses expression of the key gluconeogenic regulatory enzymes PEPCK (phosphoenolpyruvate carboxykinase) and G6Pase (glucose-6-phosphatase). The effects on FOXO1. a and gluconeogenic gene expression require the presence of Zn2+ ions, reminiscent of much earlier studies examining diabetogenic properties of 8-hydroxyquinolines. Comparative investigation of the signalling properties of a panel of these compounds demonstrates that CQ alone exhibits FOXO1a regulation without diabetogenicity. Our results suggest that Zn2+-dependent regulation of FOXOs and gluconeogenesis may contribute to the therapeutic properties of this drug. Further investigation of this signalling response might illuminate novel pharmacological strategies for the treatment of age-related diseases.

Documents

Library & Learning Centre

Contact | Accessibility | Policy